The C550 study is the largest reported phase II study that evaluated the antitumor activity of the combination of balstilimab (an anti-PD-1 antibody) with zalifrelimab (an anti-CTLA-4 antibody) as a second-line therapy for advanced cervical cancer. The gene discussed is CTLA4; the disease is cervical cancer.